Tirzepatide is a novel dual GLP1-GIP receptor agonist that has been recently shown to induce substantial and sustained body weight loss in overweight patients with or without diabetes mellitus (SURMOUNT TRIALS) [165,166]. This evidence concerns the gene GCG and diabetes mellitus.